Abstract

Treatment options for rheumatoid arthritis (RA), spondyloarthritis (SpA) and psoriatic arthritis (PsA) have improved with the introduction of biologic and targeted synthetic disease-modifying antirheumatic drugs. Although a good clinical response and even remission can be achieved in most cases, a low quality of life (QOL), depression, and chronic pain often persist and lead to an increased disease burden.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call